Skip to main content
Premium Trial:

Request an Annual Quote

New Zealand Patent Office Issues Notice of Allowance for MDRNA Application

Premium

MDRNA said this week that it has received a notice of allowance from the Intellectual Property Office of New Zealand on a patent application covering siRNAs and delivery systems with therapeutic potential.

The application, No. 553828, is entitled, "Methods of Treating an Inflammatory Disease by Double-Stranded Ribonucleic Acid," according to the company.

"Allowed claims cover small interfering RNAs directed against the tumor necrosis factor gene, as well as several of the company's key nucleic acid condensing and delivery peptide motifs in combination with a siRNA directed against TNF," MDRNA added.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.